Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on R chiral amines. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN119040289B enables high-purity chiral amine production. Reduces costs and improves supply chain reliability for pharmaceutical intermediates manufacturing globally.
Novel metal-free catalyst technology enabling high-purity chiral secondary amines with significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN119614533B reveals thermostable enzyme mutants improving R-chiral amine synthesis efficiency and supply chain stability for pharmaceutical intermediates.
Patent CN110577941B reveals mutated enzymes for high-purity chiral amine synthesis, offering cost reduction in pharmaceutical intermediate manufacturing via biocatalysis.
Patent CN110577941B details mutated amine dehydrogenase for asymmetric reductive amination, offering high optical purity and scalable biocatalysis for pharmaceutical intermediates.
Novel transaminase mutants for chiral amine production. Enhanced stability at 55°C and pH 10. Cost-effective biocatalysis for pharma intermediates.
Patent CN110577941A reveals mutated amine dehydrogenase for asymmetric reductive amination. Enables cost reduction in pharmaceutical intermediates manufacturing with high optical purity.
Patent CN100560561C discloses a high stereoselective route to chiral alpha-difluoromethylamines using sulfone reagents, offering superior purity and scalability for API manufacturing.